Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: A comparative clinical study

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 211-215

  Sobaci, Güngör ^a   Güngör, Riza ^a   Özge, Gökhan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adverse effect; Anti VEGF; Bevacizumab; Intraocular pressure; Ranibizumab; Retinal nerve fiber layer

Indexed keywords

EID: 84894555461     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.20     Document Type: Article

References (28)

1. Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol. 2009; 247(12): 1707-1710.
2. Battaglia Parodi M., Iacono P, Cascavilla M.L., Zucchiatti I., Kontadakis DS, Vergallo S, Bandello F. Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema. Eur J Ophthalmol. 2010; 20(6): 1076-1078.
3. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson J.A., Freund KB. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012; 21(4): 241-247.
4. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010; 4: 28-29.
5. Kahook MY, Kimura AE, Wong L.J., Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009; 40(3): 293-295.
6. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011; 95(8): 1111-1114.
7. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010; 26(1): 105-110.
8. Bakri SJ, McCannel CA, Edwards A.O., Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246(7): 955-958.
9. Nishijima K, Ng YS, Zhong L, Bradley J., Schubert W, Jo N, Akita J., Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor - A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007; 171(1): 53-67.
10. Lalwani GA, Rosenfeld PJ, Fung A.E., Dubovy SR, Michels S, Feuer W, Davis J.L., Flynn HW, Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
11. Aiello LP, Brucker AJ, Chang S, Cunningham E.T., Jr, D'Amico DJ, Flynn HW, Jr, Grillone LR, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, Ta C, Trese MT. Evolving guidelines for intravitreous injections. Retina. 2004; 24(5 Suppl): S3-19.
12. Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009; 20(3): 223-225.
13. Ladas ID, Karagiannis DA, Rouvas A.A., Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009; 29(3): 313-318.
14. Schmucker C, Ehlken C, Hansen L.L., Antes G., Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol. 2010; 21(3): 218-226.
15. CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20): 1897-1908.
16. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011; 25(6): 661-672.
17. Avci B, Avci R, Inan U.U., Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(7): 3438-3446.
18. Zayit-Soudry S., Zemel E, Loewenstein A., Perlman I. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 2010; 30(4): 671-681.
19. Sari A, Adiguzel U, Canacankatan N., Yilmaz N, Dinc E, Oz O. Effects of intravitreal bevacizumab in repeated doses: an experimental study. Retina. 2009; 29(9): 1346-1355.
20. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26(3): 270-274.
21. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin) Retina. 2007; 27(8): 1044-1047.
22. Kim JE, Mantravadi AV, Hur E.Y., Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146(6): 930-934.
23. Hollands H, Wong J, Bruen R., Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007; 42(6): 807-811.
24. Bakri SJ, Pulido JS, McCannel C.A., Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009; 23(1): 181-185.
25. Bayraktar S, Bayraktar Z, Yilmaz OF. Influence of scan radius correction for ocular magnification and relationship between scan radius with retinal nerve fiber layer thickness measured by optical coherence tomography. J Glaucoma. 2001; 10(3): 163-169.
26. Wu Z, Huang J, Dustin L., Sadda SR. Signal strength is an important determinant of accuracy of nerve fiber layer thickness measurement by optical coherence tomography. J Glaucoma. 2009; 18(3): 213-216.
27. Cheng CK, Peng PH, Tien L.T., Cai YJ, Chen CF, Lee YJ. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina. 2009; 29(3): 306-312.
28. Horsley MB, Mandava N, Maycotte M.A., Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010; 150(4): 558-561.